These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Perspectives on clinical trials in the rheumatic diseases. Hart FD Clin Rheum Dis; 1983 Dec; 9(3):491-8. PubMed ID: 6606529 [No Abstract] [Full Text] [Related]
8. The design of controlled experiments in the evaluation of non-therapeutic interventions. Buck C; Donner A J Chronic Dis; 1982; 35(7):531-8. PubMed ID: 7085845 [No Abstract] [Full Text] [Related]
9. Bias in treatment assignment in controlled clinical trials. N Engl J Med; 1984 Jun; 310(24):1610-2. PubMed ID: 6727931 [No Abstract] [Full Text] [Related]
10. An efficient design for phase III studies of combination chemotherapies. Ellenberg SS; Eisenberger MA Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093 [No Abstract] [Full Text] [Related]
11. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Korelitz BI; Present DH Gastroenterology; 1981 Jan; 80(1):193-6. PubMed ID: 6108892 [No Abstract] [Full Text] [Related]
12. Methodological guidelines for clinical trials evaluating new therapeutic approaches in bone and joint surgery. Raskob GE; Lofthouse RN; Hull RD J Bone Joint Surg Am; 1985 Oct; 67(8):1294-7. PubMed ID: 4055857 [No Abstract] [Full Text] [Related]
13. Design and analysis of controlled clinical trials in rheumatic diseases. Williams HJ; Reading JC; Ward JR Clin Rheum Dis; 1983 Dec; 9(3):499-514. PubMed ID: 6606530 [TBL] [Abstract][Full Text] [Related]
14. [Double-blind or open mind?]. Huttunen JK Duodecim; 1986; 102(16):1129-33. PubMed ID: 3757849 [No Abstract] [Full Text] [Related]
15. [Methodological deficiencies in clinical trials]. Nahler G Fortschr Med; 1992 Oct; 110(28):511-4. PubMed ID: 1398408 [TBL] [Abstract][Full Text] [Related]
18. Is your 'double-blind' design truly double-blind? Oxtoby A; Jones A; Robinson M Br J Psychiatry; 1989 Nov; 155():700-1. PubMed ID: 2611601 [No Abstract] [Full Text] [Related]
19. Blinding in pharmacological trials: the devil is in the details. Wan M; Orlu-Gul M; Legay H; Tuleu C Arch Dis Child; 2013 Sep; 98(9):656-9. PubMed ID: 23898156 [No Abstract] [Full Text] [Related]
20. Interpreting age-related aspects of antihypertensive treatment: statistical defects and their remedy. Murray GD; Lesaffre E; Robertson JI J Hypertens Suppl; 1988 Nov; 6(1):S121-6. PubMed ID: 3063787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]